Clinical Trial

Semaglutide 2.4 mg in Patients With Poor Weight-loss

Study acronym: BARI-STEP
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery. The primary aim of this trial is to determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients with poor weight loss following gastric bypass or sleeve gastrectomy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-28; most recent amendment 2024-12-05.
Status change: Recruiting → Active, Not Recruiting 2023-11-06
Status change: Not Yet Recruiting → Recruiting 2022-11-03
Trial Details
NCT Number NCT05073835
Lead Sponsor University College, London
Conditions Obesity, Diabetes, Metabolic Syndrome
Enrollment 70 participants
Start Date 2022-11-01
Primary Completion 2025-03 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2024-12-06